MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 85 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $451,959 | +15.7% | 56,144 | +56.1% | 0.00% | – |
| Q2 2023 | $390,667 | -33.2% | 35,973 | -57.6% | 0.00% | – |
| Q1 2023 | $584,789 | +93.7% | 84,752 | +11.8% | 0.00% | – |
| Q4 2022 | $301,827 | -52.9% | 75,836 | -21.3% | 0.00% | – |
| Q3 2022 | $641,000 | +37.8% | 96,375 | +0.2% | 0.00% | – |
| Q2 2022 | $465,000 | +46.7% | 96,197 | +183.5% | 0.00% | – |
| Q1 2022 | $317,000 | -46.9% | 33,937 | -32.4% | 0.00% | – |
| Q4 2021 | $597,000 | +63.1% | 50,214 | +56.3% | 0.00% | – |
| Q3 2021 | $366,000 | -33.5% | 32,118 | +4.8% | 0.00% | – |
| Q2 2021 | $550,000 | +69.2% | 30,651 | +45.9% | 0.00% | – |
| Q1 2021 | $325,000 | +29.0% | 21,009 | +2.0% | 0.00% | – |
| Q4 2020 | $252,000 | +38.5% | 20,597 | +45.6% | 0.00% | – |
| Q3 2020 | $182,000 | – | 14,142 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |